The comparison of circulating sclerostin levels between healthy controls and T2D patients without CVD (n = 91, 45% males) and with CVD (n = 48, 77% males) revealed significant differences between groups (p < 0.001). This evidence concerns the gene SOST and type 2 diabetes mellitus.